Health Care & Life Sciences » Pharmaceuticals | Kadmon Holdings Inc.

Kadmon Holdings Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
95,018.00
35,719.00
26,055.00
12,264.00
1,396
Cost of Goods Sold (COGS) incl. D&A
35,487.00
35,759.00
21,373.00
2,986.00
2,216
Gross Income
59,531.00
40.00
4,682.00
9,278.00
820
SG&A Expense
97,820.00
108,544.00
124,217.00
77,834.00
85,076
EBIT
38,289.00
108,584.00
119,535.00
68,556.00
85,896
Unusual Expense
390.00
35,461.00
2,665.00
2,096.00
35,600
Non Operating Income/Expense
2,399.00
24,134.00
8.00
6.00
74
Interest Expense
28,911.00
24,408.00
72,634.00
5,962.00
4,619
Pretax Income
64,385.00
147,085.00
208,413.00
79,895.00
54,776
Income Tax
29.00
3.00
342.00
121.00
524
Consolidated Net Income
64,356.00
147,082.00
208,755.00
79,774.00
54,252
Net Income
64,356.00
147,082.00
208,755.00
79,774.00
54,252
Net Income After Extraordinaries
64,356.00
147,082.00
208,755.00
79,774.00
54,252
Net Income Available to Common
64,356.00
147,082.00
230,488.00
81,692.00
56,263
EPS (Basic)
1.40
3.21
9.74
1.42
0.58
Basic Shares Outstanding
45,807.80
45,807.80
23,674.50
57,405.30
97,609
EPS (Diluted)
1.40
3.21
9.74
1.42
0.58
Diluted Shares Outstanding
45,807.80
45,807.80
23,674.50
57,405.30
97,609
EBITDA
13,841.00
78,830.00
102,032.00
66,734.00
84,362
Non-Operating Interest Income
26.00
10.00
38.00
132.00
1,307
Equity in Affiliates (Pretax)
-
2,776.00
13,625.00
7,599.00
1,242
Preferred Dividends
-
-
21,733.00
1,918.00
2,011

About Kadmon Holdings

View Profile
Address
450 East 29th Street
New York New York 10016
United States
Employees -
Website http://www.kadmon.com
Updated 07/08/2019
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. Its products include Ribasphere RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine. The company was founded by Steven N.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.